Skip to main content
OpenTrials

Clinical trial condition

Myeloproliferative Disorders

Explore clinical trials studying Myeloproliferative Disorders. Study availability and eligibility vary by location and protocol.

1,121 public trials 145 recruiting studies
Refine in advanced search Browse all conditions

Myeloproliferative Disorders trial results

Recruiting

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

NCT07357727

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations
  • Summit Medical Group Oncology Berkeley Heights, New Jersey, United States
  • The Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • Novartis Investigative Site Buenos Aires, Buenos Aires F.D., Argentina
  • Novartis Investigative Site Capital Federal, Argentina
View all 96 locations
View Trial Details
Recruiting

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

NCT04925479

Conditions
Bone Marrow Diseases, Chronic Disease, Disease Attributes, +11 more
Locations
  • Indiana UH Riley H for CIU Indianapolis, Indiana, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • University of Mississippi Medical Center Jackson, Mississippi, United States
  • Columbia University Medical Center New York Presbyterian New York, United States
View all 39 locations
View Trial Details
Recruiting

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

NCT04176198

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +3 more
Locations
  • University of Alabama Birmingham, Alabama, United States
  • The University of Arizona Cancer Center Tucson, Arizona, United States
  • City of Hope Duarte, California, United States
  • University of Southern California Los Angeles, California, United States
View all 91 locations
View Trial Details
Recruiting

A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

NCT06343805

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +2 more
Locations
  • Stanford Cancer Institute Palo Alto, California, United States
  • Moffitt Cancer Cancer Center Tampa, Florida, United States
  • University of Kansas Medical Center Kansas City, Kansas, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
View all 21 locations
View Trial Details

Related conditions